Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo.

Fenstermaker RA, Figel SA, Qiu J, Barone TA, Dharma SS, Winograd EK, Galbo PM, Wiltsie LM, Ciesielski MJ.

Clin Cancer Res. 2018 Jun 1;24(11):2642-2652. doi: 10.1158/1078-0432.CCR-17-2778. Epub 2018 Mar 14.

PMID:
29540489
2.

Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination.

Galbo PM Jr, Ciesielski MJ, Figel S, Maguire O, Qiu J, Wiltsie L, Minderman H, Fenstermaker RA.

Oncotarget. 2017 Oct 10;8(70):114722-114735. doi: 10.18632/oncotarget.21773. eCollection 2017 Dec 29.

3.

TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.

Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L.

Clin Cancer Res. 2017 Nov 15;23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. Epub 2017 Sep 12.

PMID:
28899973
4.

Association of susceptibility to certain hematopoietic malignancies with the presence of Ia allodeterminants distinct from the DR series; utility of monoclonal antibody reagents.

Winchester R, Toguchi T, Szer I, Burmester G, Lo Galbo P, Cuttner J, Capra JD, Nunez-Roldan A.

Immunol Rev. 1983;70:155-66.

PMID:
6187661

Supplemental Content

Support Center